Promising results of novel combination HIV vaccine

Results from a recent study show that novel vaccine combinations can provide partial protection against infection by Simian Immunodeficiency Virus (SIV) in rhesus monkeys. In addition, in the animals that became infected, the optimal vaccine combinations also substantially reduced the amount of virus in the blood. Results from the studies were published online today in the journal Nature.

Read more

Plasma-based treatment goes viral

Life-threatening viruses such as HIV, SARS, hepatitis and influenza, could soon be combatted in an unusual manner as researchers have demonstrated the effectiveness of plasma for inactivating and preventing the replication of adenoviruses.

Read more

End to the 30-year war against AIDS in sight

Thirty years, 30 million deaths and 60 million infections after HIV appeared, medical researchers now have the tools to halt the deadly epidemic.

“We have the weapons to win the war against AIDS,” says Richard Marlink, M.D., Executive Director of the AIDS Initiative at the Harvard School of Public Health. “It is time to take what we have learned to turn the epidemic around and end AIDS.”

Read more

First combination ARV vaginal ring for HIV prevention being tested in Phase I safety trial

In the first clinical trial of a vaginal ring combining two antiretroviral (ARV) drugs, researchers from the Microbicide Trials Network (MTN) are collaborating with the International Partnership for Microbicides (IPM) to evaluate whether the ring is safe for use in women. If the ring does prove to be safe, it could be considered for further testing, and eventually be evaluated for its effectiveness as a microbicide for protecting women against HIV infection through vaginal sex.

Read more

A Trojan horse in the fight against HIV/AIDS

Montreal, Quebec, Canada – The Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM) announced today that one of its researchers will receive funding of 100,000 US $ through Grand Challenges Explorations, an initiative created by the Bill & Melinda Gates Foundation that enables researchers worldwide to test unorthodox ideas that address persistent health and development challenges. Dr. Andrés Finzi will pursue an innovative global health research project, titled “Reverse Fusion: a new approach to eradicate HIV/AIDS” to deliver toxic genes to HIV-infected cells and eliminate them.

Read more

Potential new drugs plug brain’s biological ‘vacuum cleaner’ and target HIV

In an advance toward eliminating pockets of infection in the brain that help make HIV disease incurable, scientists report the development of new substances that first plug the biological vacuum cleaner that prevents anti-HIV drugs from reaching the brain and then revert to an active drug to treat HIV. They describe the advance, which allows medications to cross the so-called “blood-brain barrier” (BBB) and treat brain diseases, in the Journal of the American Chemical Society.

Read more

Targeting HIV’s sugar coating

University of Utah researchers have discovered a new class of compounds that stick to the sugary coating of the AIDS virus and inhibit it from infecting cells – an early step toward a new treatment to prevent sexual transmission of the virus.

Read more

New TB vaccine enters proof-of-concept trial in people living with HIV

Vaccine candidate is the most clinically advanced of a new generation of vaccines under development to combat TB and the TB/HIV co-epidemic

This press release is available in French.

Read more

USC scientist develops virus that targets HIV

Using a virus to kill a virus

In what represents an important step toward curing HIV, a USC scientist has created a virus that hunts down HIV-infected cells.

Dr. Pin Wang’s lentiviral vector latches onto HIV-infected cells, flagging them with what is called “suicide gene therapy” — allowing drugs to later target and destroy them.

Read more

Caltech researchers increase the potency of HIV-battling proteins

PASADENA, Calif.—If one is good, two can sometimes be better. Researchers at the California Institute of Technology (Caltech) have certainly found this to be the case when it comes to a small HIV-fighting protein.

Read more

Next Page »